HOME Top Market Reports Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019

By: marketsandmarkets.com
Publishing Date: January 2015
Report Code: BT 3113

 

  Speak to Analyst Enquiry Before Buying
 
purchase report
download pdf  request for customisation


The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market. Emerging economies such as India and China present an array of opportunities for this market.

North America dominates the market, with the U.S. accounting for a major market share. However, Asia is poised to grow at the highest CAGR during the forecast period owing to the governmental initiatives, rising focus of major players on the Indian vaccine technology market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.

Prominent market players of vaccines technology  market are Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).

Scope of the Report

This research report covers the vaccines market by type, technology, disease indication, end user, and geography.

Vaccines Market, by Type

  • Preventive Vaccines
  • Therapeutic Vaccines

Vaccines Market, by Technology

  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • Subunit Vaccines
  • Recombinant Vector Vaccines
  • Inactivated Vaccines
  • Synthetic Vaccines
  • Dendritic Cells Vaccines

Vaccines Market, by Disease Indication

  • Infectious Diseases
    • Pneumococcal
    • Influenza
    • DTP
    • Hepatitis
    • Rotavirus
    • Varicella
    • Meningococcal
    • Polio
    • MMR
    • Others
  • Cancer
    • Cervical cancer
    • Others
  • Allergy

Vaccines Market, by End User

  • Pediatrics
  • Adults

Vaccines Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia
    • Japan
    • China
    • India
    • Rest of Asia
  • Rest of the World (RoW)

Table of Contents  
  
1 Introduction (Page No. - 17)
    1.1 Objectives of the Study 
    1.2 Market Definition 
    1.3 Market Scope 
           1.3.1 Markets Covered 
           1.3.2 Years Considered for the Study 
    1.4 Currency 
    1.5 Limitations 
    1.6 Stakeholders 

2 Research Methodology (Page No. - 22)
    2.1 Market Size Estimation 
    2.2 Market Breakdown and Data Triangulation 
    2.3 Market Share Estimation 
    2.4 Key Data From Secondary Sources 
    2.5 Key Data From Primary Sources 
    2.6 Key Industry Insights 
    2.7 Assumptions 

3 Executive Summary (Page No. - 30)

4 Premium Insights (Page No. - 35)
    4.1 Vaccine Technology Market to Have High Growth Potential 
    4.2 Global Vaccine Technology Market, By Type 
    4.3 Global Vaccine Technology Market, By Region 
    4.4 Vaccine Technology Market, By Disease Indication 
    4.5 Global Vaccine Technology Market, By End Users 
    4.6 Lifecycle Analysis, By Region 

5 Market Overview (Page No. - 41)
    5.1 Introduction 
    5.2 Market Segmentation 
           5.2.1 By Type 
           5.2.2 By Disease Indication 
           5.2.3 By End User 
           5.2.4 By Region 
    5.3 Market Dynamics 
           5.3.1 Drivers 
                    5.3.1.1 High Prevalence of Diseases 
                    5.3.1.2 Rising Government and Non-Government Funding for Vaccine Development 
                    5.3.1.3 Increasing Investments By Companies 
                    5.3.1.4 Technological Advancements 
           5.3.2 Restraints 
                    5.3.2.1 Huge Capital Investments 
                    5.3.2.2 Stringent Regulatory Procedures 
           5.3.3 Opportunities 
                    5.3.3.1 High Growth Prospects in Emerging Markets 
                    5.3.3.2 Therapeutic Vaccines 
                    5.3.3.3 Adjuvant Vaccines 
           5.3.4 Challenges 
                    5.3.4.1 Inadequate Access to Vaccines 
                    5.3.4.2 Vaccine Pricing 
           5.3.5 Burning Issues 
                    5.3.5.1 Failure of Vaccines 

6 Industry Insights (Page No. - 53)
    6.1 Porter’s Five Forces Analysis 
           6.1.1 Threat From New Entrants 
           6.1.2 Bargaining Power of Suppliers 
           6.1.3 Bargaining Power of Buyers 
           6.1.4 Intensity of Competitive Rivalry 
           6.1.5 Threat of Substitutes 
    6.2 Value Chain Analysis 
    6.3 Supply Chain Analysis 
    6.4 Technology Trends 
           6.4.1 Drivers 
                    6.4.1.1 Increasing Use of Adjuvants in Vaccine-Preventable Diseases 
                    6.4.1.2 Rising Government Investments 
           6.4.2 Restrains 
                    6.4.2.1 High Cost of Research 
                    6.4.2.2 Regulatory Hurdles 
           6.4.3 Opportunities 
                    6.4.3.1 Combined Adjuvants 
                    6.4.3.2 Vaccines for Young Children 
                    6.4.3.3 Pandemic Diseases 
           6.4.4 Challenges 
                    6.4.4.1 Identification of Adjuvants 
                    6.4.4.2 Technological Limitations 
           6.4.5 Trends 
                    6.4.5.1 Collaborations 
                    6.4.5.2 New Adjuvant Technologies 
    6.5 Investment Analysis 
    6.6 Regulatory Landscape 
           6.6.1 North America 
           6.6.2 Europe 
           6.6.3 Asia 
           6.6.4 ROW 
    6.7 Patent Analysis 
    6.8 Key Pipeline Products 
    6.9 Strategic Benchmarking 

7 Vaccines Market, By Technology (Page No. - 74)
    7.1 Subunit Vaccines 
    7.2 Live Attenuated Vaccines 
    7.3 Conjugate Vaccines 
    7.4 Inactivated Vaccines 
    7.5 Recombinant Vector Vaccines 
    7.6 Toxoid Vaccines 
    7.7 Synthetic Vaccines 
    7.8 Dendritic Cell Vaccines 

8 Vaccines Market, By Type (Page No. - 97)
    8.1 Introduction 
    8.2 Preventive Vaccines 
    8.3 Therapeutic Vaccines 

9 Vaccines Market, By Disease Indication (Page No. - 108)
    9.1 Introduction 
    9.2 Infectious Diseases 
           9.2.1 Pneumonia 
           9.2.2 Influenza 
           9.2.3 DTP 
           9.2.4 Hepatitis 
           9.2.5 Rotavirus 
           9.2.6 Varicella 
           9.2.7 Meningococcal 
           9.2.8 Polio 
           9.2.9 MMR 
           9.2.10 Others 
    9.3 Cancer 
           9.3.1 Cervical Cancer 
           9.3.2 Others 
    9.4 Allergies 

10 Vaccines Market, By End User (Page No. - 126)
     10.1 Introduction 
     10.2 Pediatrics 
     10.3 Adults 

11 Global Vaccine Technology Market, By Region (Page No. - 136)
     11.1 Introduction 
     11.2 North America 
             11.2.1 U.S. 
             11.2.2 Canada 
     11.3 Europe 
             11.3.1 Germany 
             11.3.2 France 
             11.3.3 U.K. 
             11.3.4 Italy 
             11.3.5 Spain 
             11.3.6 Rest of Europe (ROE) 
     11.4 Asia 
             11.4.1 Japan 
             11.4.2 China 
             11.4.3 India 
             11.4.4 Rest of Asia (ROA) 
     11.5 Rest of the World (ROW) 

12 Competitive Landscape (Page No. - 179)
     12.1 Overview 
     12.2 Market Share Analysis 
     12.3 Competitive Situation and Trends 
             12.3.1 Agreements, Collaborations & Partnerships 
             12.3.2 Regulatory Approvals 
             12.3.3 Acquisitions 
             12.3.4 Other Developments 

13 Company Profiles (Page No. - 187)
     13.1 Glaxosmithkline, PLC. 
             13.1.1 Business Overview 
             13.1.2 Product Portfolio 
             13.1.3 Key Strategies 
             13.1.4 Recent Developments 
             13.1.5 MNM View 
     13.2 Merck & Co., Inc. 
             13.2.1 Business Overview 
             13.2.2 Product Portfolio 
             13.2.3 Key Strategy 
             13.2.4 Recent Developments 
             13.2.5 MNM View 
     13.3 SANOFI 
             13.3.1 Business Overview 
             13.3.2 Product Portfolio 
             13.3.3 Key Strategy 
             13.3.4 Recent Developments 
             13.3.5 MNM View 
     13.4 Pfizer, Inc. 
             13.4.1 Business Overview 
             13.4.2 Product Portfolio 
             13.4.3 Key Strategy 
             13.4.4 Recent Developments 
             13.4.5 MNM View 
     13.5 Novartis AG 
             13.5.1 Business Overview 
             13.5.2 Product Portfolio 
             13.5.3 Key Strategy 
             13.5.4 Recent Developments 
             13.5.5 MNM View 
     13.6 Bavarian Nordic 
             13.6.1 Business Overview 
             13.6.2 Product Portfolio 
             13.6.3 Key Strategy 
             13.6.4 Recent Developments 
     13.7 CSL Limited 
             13.7.1 Business Overview 
             13.7.2 Product Portfolio 
             13.7.3 Key Strategy 
             13.7.4 Recent Developments 
     13.8 Emergent Biosolutions, Inc. 
             13.8.1 Business Overview 
             13.8.2 Product Portfolio 
             13.8.3 Key Strategy 
             13.8.4 Recent Developments 
     13.9 Johnson & Johnson 
             13.9.1 Business Overview 
             13.9.2 Product Portfolio 
             13.9.3 Key Strategy 
             13.9.4 Recent Developments 
     13.10 Medimmune, LLC. (A Subsidiary of Astrazeneca) 
             13.10.1 Business Overview 
             13.10.2 Product Portfolio 
             13.10.3 Key Strategy 
             13.10.4 Recent Developments 

14 Appendix (Page No. - 216)
     14.1 Insights From Industry Experts 
     14.2 Discussion Guide 
     14.3 Available Customizations 
     14.4 Related Reports 
     14.5 Introducing RT: Real-Time Market Intelligence 
  
  
List of Tables (145 Tables)  
   
Table 1 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines 
Table 2 Huge Capital Investment to Limit the Market Growth of Vaccines 
Table 3 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines 
Table 4 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines 
Table 1 National Institutes of Health (NIH) Funding for Vaccine Development, 2011–2013 ($Million) 
Table 2 Regulatory Authorities in Europe 
Table 3 Regulatory Authorities in Asia 
Table 4 Key Pipeline Vaccines 
Table 5 Vaccine Market Size, By Technology, 2012-2019 ($Million) 
Table 6 Subunit Vaccine Market Size, By Region, 2012-2019 ($Million) 
Table 7 North America: Subunit Vaccine Market Size, By Country, 2012-2019 ($Million) 
Table 8 Europe: Subunit Vaccines Market Size, By Country,  2012-2019 ($Million) 
Table 9 Asia: Subunit Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 10 Live Attenuated Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 11 North America: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 12 Europe: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 13 Asia: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 14 Conjugate Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 15 North America: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 16 Europe: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 17 Asia: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 18 Inactivated Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 19 North America: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 20 Europe: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 21 Asia: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 22 Recombinant Vector Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 23 North America: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 24 Europe: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 25 Asia: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 26 Toxoid Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 27 North America: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 28 Europe: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 29 Asia: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 30 Synthetic Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 31 North America: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 32 Europe: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 33 Asia: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 34 Dendritic Cell Vaccines Market Size, By Region, 2012-2019 ($Million) 
Table 35 North America: Dendritic Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 36 Europe: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 37 Asia: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million) 
Table 38 Vaccines Market Size, By Type, 2012–2019 ($Million) 
Table 39 Preventive Vaccines Market Size, By Region, 2012–2019 ($Million) 
Table 40 North America: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million) 
Table 41 Europe: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million) 
Table 42 Asia: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million) 
Table 43 Therapeutic Vaccines Market Size, By Region, 2012–2019 ($Million) 
Table 44 North America: Therapeutic Vaccines Market Size, By Country, 2012–2019 ($Million) 
Table 45 Europe: Therapeutic Vaccine Market Size, By Country, 2012–2019 ($Million) 
Table 46 Asia: Therapeutic Vaccines Market Size, By Country, 2012–2019 ($Million) 
Table 47 Vaccines Market Size, By Disease Indication, 2012–2019 ($Million) 
Table 48 Vaccines Market Size for Infectious Diseases, By Region, 2012-2019 ($Million) 
Table 49 North America: Vaccines Market Size for Infectious Diseases, By Country, 2012–2019 ($Million) 
Table 50 Europe: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012–2019 ($Million) 
Table 51 Asia: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012-2019 ($Million) 
Table 52 Infectious Diseases Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 53 Vaccine Technology Market Size for Cancer, By Region, 2012–2019 ($Million) 
Table 54 North America: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million) 
Table 55 Europe: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million) 
Table 56 Asia: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million) 
Table 57 Cancer Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 58 Vaccine Technology Market Size for Allergies, By Region, 2012–2019 ($Million) 
Table 59 North America: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million) 
Table 60 Europe: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million) 
Table 61 Asia: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million) 
Table 62 Vaccine Technology Market Size, By End User, 2012–2019 ($Million) 
Table 63 Vaccine Technology Market Size for Pediatrics, By Region, 2012–2019 ($Million) 
Table 64 North America: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million) 
Table 65 Europe: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million) 
Table 66 Asia: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million) 
Table 67 Vaccine Technology Market Size for Adults, By Region, 2012–2019 ($Million) 
Table 68 North America: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million) 
Table 69 Europe: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million) 
Table 70 Asia: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million) 
Table 71 Vaccine Technology Market Size, By Region, 2012–2019 ($Million) 
Table 72 North America: Vaccine Technology Market Size, By Country, 2012–2019 ($Million) 
Table 73 Europe: Vaccine Technology Market Size, By Country, 2012–2019 ($Million) 
Table 74 Asia: Vaccine Technology Market Size, By Country, 2012–2019 ($Million) 
Table 75 North America: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 76 North America: Market Size, By Type, 2012-2019 ($Million) 
Table 77 North America: Size, Market By Disease Indication, 2012-2019 ($Million) 
Table 78 North America: Market Size, By End Users, 2012-2019 ($Million) 
Table 79 U.S.: Vaccine Market Size, By Technology, 2012-2019 ($Million) 
Table 80 U.S.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 81 U.S.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 82 U.S.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 83 Canada: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 84 Canada: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 85 Canada: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 86 Canada: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 87 Europe: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 88 Europe: Market Size, By Type, 2012-2019 ($Million) 
Table 89 Europe: Market , By Disease Indication, 2012-2019 ($Million) 
Table 90 Europe: Market Size, By End Users, 2012-2019 ($Million) 
Table 91 Germany: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 92 Germany: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 93 Germany: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 94 Germany: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 95 France: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 96 France: Market Size, By Type, 2012-2019 ($Million) 
Table 97 France: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 98 France: Market Size, By End Users, 2012-2019 ($Million) 
Table 99 U.K. : Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 100 U.K.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 101 U.K.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 102 U.K.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 103 Italy: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 104 Italy: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 105 Italy: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 106 Italy: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 107 Spain: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 108 Spain: Vaccines  Market Size, By Type, 2012-2019 ($Million) 
Table 109 Spain: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 110 Spain:  Market Size, By End Users, 2012-2019 ($Million) 
Table 111 ROE: Market Size, By Technology, 2012-2019 ($Million) 
Table 112 ROE: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 113 ROE: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 114 ROE: Market Size, By End Users, 2012-2019 ($Million) 
Table 115 Asia: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 116 Asia: Market Size, By Type, 2012-2019 ($Million) 
Table 117 Asia: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 118 Asia: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 119 Japan: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 120 Japan: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 121 Japan: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 122 Japan: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 123 China: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 124 China: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 125 China: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 126 China: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 127 India: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 128 India: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 129 India: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 130 India: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 131 ROA: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million) 
Table 132 ROA: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 133 ROA: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 134 ROA: Market Size, By End Users, 2012-2019 ($Million) 
Table 135 ROW: Market Size, By Technology, 2012-2019 ($Million) 
Table 136 ROW: Vaccine Technology Market Size, By Type, 2012-2019 ($Million) 
Table 137 ROW: Market Size, By Disease Indication, 2012-2019 ($Million) 
Table 138 ROW: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million) 
Table 139 Recent Agreements and Collaborations 
Table 140 Recent Regulatory Approvals 
Table 141 Recent Acquisitions 
Table 142 Recent Other Developments 
Table 143 Exchange Rates (Utilized for Conversion of GBP to USD) 
Table 144 Exchange Rates (Utilized for Conversion of EURO to USD) 
Table 145 Exchange Rates (Utilized for the Conversion of DKK to USD) 
  
  
List of Figures (65 Figures)  
  
Figure 1 Vaccines Market, By Technology 
Figure 2 Research Methodology 
Figure 3 Top-Down Approach 
Figure 4 Bottom-Up Approach 
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region 
Figure 6 Data Triangulation Methodology 
Figure 7 Vaccine Technology Market Snapshot (2014 vs. 2019): Sub-Unit Vaccines to Grow at Highest CAGR 
Figure 8 Preventive Vaccines to Dominate the Vaccines Market 
Figure 9 Pediatric Segment Will Be the Largest End-User Segment in the Vaccines Market 
Figure 10 North America to Hold Largest Share in the Global Vaccines Market 
Figure 11 Market Growth Will Be Driven By Prevalence of Diseases 
Figure 12 Preventive Vaccines Segment Held the Largest Share in Vaccines Market, By Type 
Figure 13 U.S. Commands One-Third of the Market 
Figure 14 Infectious Diseases Segment Has A Promising Future in Emerging Economies 
Figure 15 Pediatrics Segment Will Continue to Lead the Vaccines End-Users Market During the Forecast Period 
Figure 16 Asia to Witness High Growth Rate in the Vaccines Market During Forecast Period 
Figure 17 Vaccines Market Segmentation: By Type 
Figure 18 Vaccines Market Segmentation: By Disease Indication 
Figure 19 Vaccines Market Segmentation: By End User 
Figure 20 Vaccines Market Segmentation: By Region 
Figure 21 Increasing Government Support for Pandemic Threats Likely to Fuel Growth of Vaccines Market 
Figure 22 Porter’s Five Forces Analysis 
Figure 23 Value Chain Analysis: Major Value is Added During the Development and Manufacturing Phases 
Figure 24 Supply Chain Analysis 
Figure 25 Cold Chain Management 
Figure 26 FDA-Approved Vaccine Adjuvants 
Figure 27 Licensed Vaccines Containing Adjuvants 
Figure 28 Examples of Vaccine Adjuvants in Clinical Trials 
Figure 29 Investors Play an Important Role in the Vaccines Market 
Figure 30 Vaccine Research Funding, By Type of Investor 
Figure 31 U.S. Government Agencies Held Largest Share of the HIV R&D Funding in 2013 
Figure 32 Regulatory Approval Process for Vaccines 
Figure 33 North America Accounted for the Largest Number of Patent Filings in 2012 
Figure 34 The U.S. Accounted for Largest Number of Patent Filings Across the Globe (2012) 
Figure 35 Strategic Benchmarking: Glaxosmithkline, PLC. Largely Adopted Inorganic Growth Strategies for Enhancing Product Offerings 
Figure 36 Subunit Vaccines Segment to Grow at Highest CAGR in Forecast Period 
Figure 37 North America to Dominate the Inactivated Vaccines Market From  2014 to 2019  
Figure 38 Toxoid Vaccines Market in Asia Will Grow at Highest CAGR From  2014 to 2019  
Figure 39 Reference Figure 
Figure 40 Preventive Vaccines to Dominate the Global Vaccines Market From 2014 to 2019 
Figure 41 Asia to Grow at the Highest CAGR From 2014 to 2019 
Figure 42 Infectious Diseases Segment to Dominate the Vaccines Market From 2014 to 2019 
Figure 43 The Pediatrics End-User Segment Will Drive the Vaccines Market During the Forecast Period 
Figure 44 Geographic Snapshot (2014): Emerging Markets Hold Growth Opportunities 
Figure 45 Geographic Benchmarking for Vaccine Technology Market 
Figure 46 Market Growth Will Be Driven By Increasing R&D Activities for Development of Vaccines 
Figure 47 Infectious Diseases Segment Will Continue to Drive the Vaccines Market 
Figure 48 Germany Will Continue to Dominate the Vaccines Market in Europe 
Figure 49 German Vaccines Market to Grow at the Highest CAGR in Europe 
Figure 50 Asia Will Grow at the Highest CAGR in the Vaccines Market 
Figure 51 Indian Vaccines Market Will Have High Growth Potential 
Figure 52 Preventive Vaccines Will Lead the Vaccines Market of ROW in 2019 
Figure 53 Major Players Signed Agreements to Enhance Their Market Positions in the Vaccines Market 
Figure 54 Global Vaccines Market Share, By Key Player, 2013 
Figure 55 Battle for Market Share: Agreements Was the Key Strategy Adopted  By Market Players  
Figure 56 Glaxosmithkline, PLC.: Company Snapshot 
Figure 57 Merck & Co., Inc.: Company Snapshot 
Figure 58 SANOFI: Company Snapshot 
Figure 59 Pfizer Inc.: Company Snapshot 
Figure 60 Novartis AG: Company Snapshot 
Figure 61 Bavarian Nordic: Company Snapshot 
Figure 62 CSL Limited: Company Snapshot 
Figure 63 Emergent Biosolutions: Company Snapshot 
Figure 64 Johnson & Johnson: Company Snapshot 
Figure 65 Astrazeneca : Company Snapshot

The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market.

The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. This market is segmented on the basis of type, technology, disease indication, end user, and geography.

The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market.

On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of  market.

The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others.

On the basis of end users, the vaccine technology market is segmented into pediatrics and adults. Pediatrics is the major end user of market. High prevalence of diseases such as tuberculosis, mumps, and meningitis will boost the growth of this segment.

Vaccines Market, by Geography, 2014

Vaccine Market

Source: Annual Reports, SEC Filings, Investors Presentations, World Health Organization (WHO), International Society of Vaccines (ISV), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), International Medical Council on Vaccination, United Nations Children's Fund (UNICEF), GAVI Alliance, Pan American Health Organization (PAHO), Asia-Pacific Alliance for the Control of Influenza (APACI), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Expert Interviews, and MarketsandMarkets Analysis

The global market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the global market in the forecast period. However, Asia is expected to be the fastest-growing market, with growth centered on China, India, and Japan.

Key players in the vaccine technology market include Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports